Synthesis, spectral and thermal studies of the sodium salts of some Ru(III) complexes with quinolone antibiotics

被引:7
作者
Badea, Mihaela [1 ]
Olar, Rodica [1 ]
Silvestro, Luigi [2 ]
Maurer, Martin [3 ]
Uivarosi, Valentina [4 ]
机构
[1] Univ Bucharest, Dept Inorgan Chem, Fac Chem, 90-92 Panduri St,Sect 5, Bucharest 050663, Romania
[2] Pharma Serv Int SRL, 52 Sabinelor St,Sect 5, Bucharest 050853, Romania
[3] 3S Pharmacol Consultat Res GmbH, 1 Koenigsbergerstr, D-27243 Harpstedt, Germany
[4] Carol Davila Univ Med & Pharm, Dept Gen Inorgan Chem, 6 Traian Vuia St, Bucharest 020956, Romania
关键词
Quinolone derivative; Ruthenium(III) complex; Sodium salt; Thermal stability; PHASE-I; DECOMPOSITION;
D O I
10.1007/s10973-016-5902-z
中图分类号
O414.1 [热力学];
学科分类号
摘要
Solubilisation by salt formation is an effective method to increase the solubility of slightly soluble drugs, applied especially for the development of liquid formulations for parenteral administration. In the present study, this strategy is applied for new Ru(III) complexes with quinolone antibiotics, valuable for biological application such as anticancer activity. The parent compounds, formulated as RuCl (3) (HL) (2) (DMSO) (m) (H (2) O) (n) (HL: pipemidic acid, norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, enrofloxacin, enoxacin), were transformed in their corresponding soluble sodium salts with general formula Na (2) RuCl (3) (L) (2) (DMSO) (m) (EtOH) (n) (H (2) O) (p) . The sodium salts have been characterised by elemental analysis and some spectrometric methods (IR, UV-Vis, mass spectra). The thermal behaviour of these newly compounds was studied by simultaneous TG/DTG/DTA analysis, and it was evidenced a higher thermal stability compared to that of the parent compounds. The thermal transformations occur in two or three steps and comprise solvent (solvation or coordination) elimination as well as oxidative degradation of quinolone derivatives. A mixture of ruthenium and sodium chloride was identified as final residue.
引用
收藏
页码:721 / 729
页数:9
相关论文
共 23 条
[1]  
[Anonymous], [No title captured], Patent No. 9800431
[2]  
Badea M, 2009, J THERM ANAL CALORIM, V97, P35
[3]   Thermal study of some new quinolone ruthenium(III) complexes with potential cytostatic activity [J].
Badea, Mihaela ;
Olar, Rodica ;
Marinescu, Dana ;
Uivarosi, Valentina ;
Nicolescu, Teodor Octavian ;
Iacob, Daniela .
JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2010, 99 (03) :829-834
[4]   Thermal decomposition of new ruthenium(II) complexes containing N-alkylphenothiazines [J].
Hollo, Berta ;
Krstic, Milena ;
Sovilj, Sofija P. ;
Pokol, Gyoergy ;
Szecsenyi, Katalin Meszaros .
JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2011, 105 (01) :27-32
[5]   Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells [J].
Kapitza, S ;
Pongratz, M ;
Jakupec, MA ;
Heffeter, P ;
Berger, W ;
Lackinger, L ;
Keppler, BK ;
Marian, B .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (02) :101-110
[6]  
Keller H, 1989, US Patent, Patent No. 4843069
[7]  
Kratochvil B., 2011, GLASSY AMORPHOUS DIS, P136
[8]   Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study [J].
Lentz, Frederike ;
Drescher, Anne ;
Lindauer, Andreas ;
Henke, Magdalena ;
Hilger, Ralf A. ;
Hartinger, Christian G. ;
Scheulen, Max E. ;
Dittrich, Christian ;
Keppler, Bernhard K. ;
Jaehde, Ulrich .
ANTI-CANCER DRUGS, 2009, 20 (02) :97-103
[9]  
Lever ABP, 1986, INORGANIC ELECT SPEC, P454
[10]  
Mestroni G, 1994, Met Based Drugs, V1, P41